HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.

Upcoming Events

HepQuant will be attending / presenting at the following local, national or international meetings:

EASL 2020 | London, UK | August 25-28

AASLD | Boston, Massachusetts | November 13 – 17, 2020

NASH Summit | Boston, Massachusetts | December 16-17, 2020

Liver / PSC Forum | Washington, DC | January 29-31, 2021

Recent Events

Digestive Disease Week (DDW) | Virtual | May 3, 2020

• “Predicting Decompensation, Death, or Liver Transplantation in Cirrhosis by Using a Non-Invasive Liver Function Test (HepQuant SHUNT)”, an oral Presentation | Abstract

HCC-TAG 2020 | Park City, Utah | February 27 – 29, 2020 | Conference Website

• The HepQuant SHUNT Test of Global Liver Function and Physiology Identifies the Patients with Advanced Fibrosis or Compensated Cirrhosis Who are At-Risk for Hepatocellular Carcinoma | Poster | Abstract
• Deterioration in Liver Function after Liver-Directed Therapy for Hepatocellular Carcinoma Measured by Cholate Clearance | Poster | Abstract

Interview at BioTech 2020 | “Director Interview”

HepQuant CEO Greg Everson joined Proactive at the Biotech Showcase 2020 in San Francisco, Jan. 14th, 2020.

NASH Summit 2019

Greg Everson, MD, HepQuant’s Chief Executive Officer, presented at the NASH Summit 2019, in Boston. Dr. Everson was a key speaker during the Clinical Stream Segment entitled “Strategic Considerations for Phase 3 Clinical Trials.” Also attending on behalf of HepQuant were Randy Dietrich and Brad Everson.